Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Jul 5:11:1179299X19860815.
doi: 10.1177/1179299X19860815. eCollection 2019.

Chemotherapy Resistance in Advanced Ovarian Cancer Patients

Ruchika Pokhriyal  1 , Roopa Hariprasad  2 , Lalit Kumar  3 , Gururao Hariprasad  1
Affiliations
Review

Chemotherapy Resistance in Advanced Ovarian Cancer Patients

Ruchika Pokhriyal et al. Biomark Cancer. .

Abstract

Ovarian cancer is the seventh most common gynaecologic malignancy seen in women. Majority of the patients with ovarian cancer are diagnosed at the advanced stage making prognosis poor. The standard management of advanced ovarian cancer includes tumour debulking surgery followed by chemotherapy. Various types of chemotherapeutic regimens have been used to treat advanced ovarian cancer, but the most promising and the currently used standard first-line treatment is carboplatin and paclitaxel. Despite improved clinical response and survival to this combination of chemotherapy, numerous patients either undergo relapse or succumb to the disease as a result of chemotherapy resistance. To understand this phenomenon at a cellular level, various macromolecules such as DNA, messenger RNA and proteins have been developed as biomarkers for chemotherapy response. This review comprehensively summarizes the problem that pertains to chemotherapy resistance in advanced ovarian cancer and provides a good overview of the various biomarkers that have been developed in this field.

Keywords: Chemo-therapy; advanced ovarian cancer; biomarkers; proteomics.

PubMed Disclaimer

Conflict of interest statement

Declaration of conflicting interests:The author(s) declared no potential conflicts of interest with respect to the research, authorship and/or publication of this article.

Figures

Figure 1.
Figure 1.
Mechanism of action of cisplatin. Double stranded DNA is shown in black; Cisplatin is shown as a brown oval; and purine bases are shown as blue coloured lines.
See this image and copyright information in PMC

References

    1. Cannistra SA. Cancer of the ovary. N Engl J Med. 2004;351:2519–2529. - PubMed
    1. Ferlay J, Ervik M, Lam F, et al. Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer, 2018.
    1. Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975–2008 (Based on November 2010 SEER Data Submission, Posted to the SEER Web Site, 2011). Bethesda, MD: National Cancer Institute; http://seer.cancer.gov/csr/1975_2008/
    1. Yancik R. Ovarian cancer: age contrasts in incidence, histology, disease stage at diagnosis, and mortality. Cancer. 1993;71:517–523. - PubMed
    1. Holschneider CH, Berek JS. Ovarian cancer: epidemiology, biology, and prognostic factors. Semin Surg Oncol. 2000;19:3–10. - PubMed

LinkOut - more resources